Compare AbCellera Biologics Inc (ABCL) vs Deere & Company (DE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Deere & Company — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Deere & Company trades at $594.6 (market cap $162.94B). The key difference: Deere & Company is far larger — about 69.3× AbCellera Biologics Inc's market cap, and Deere & Company pays a 1.07% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DE | |
|---|---|---|
Market Cap | $2.35B | $162.94B |
Sector | Health | Industrials |
52-Week High | $8.12 | $662.49 |
52-Week Low | $2.78 | $439.11 |
Enterprise Value | $1.99B | $217.76B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Deere & Company (DE) trades at $603.61, down 2.84% on the day, with the stock showing strong technical momentum despite recent volatility. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $6.55 exceeding estimates by 15%. Fundamentals remain solid with 10.33% net margins and 18.51% ROE, though revenue declined to $44.67B in 2025. Analyst consensus points to 39% buy ratings with a $666.08 price target, representing 10% upside potential.
DE presents a mixed outlook with strong operational execution offset by cyclical headwinds in agricultural equipment demand. The precision agriculture platform offers growth potential, but investors face risks from economic sensitivity and margin pressure. Current valuation at 36x P/E appears elevated relative to historical norms, requiring continued earnings growth to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
